<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183128</url>
  </required_header>
  <id_info>
    <org_study_id>SERES-012</org_study_id>
    <nct_id>NCT03183128</nct_id>
  </id_info>
  <brief_title>ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>ECOSPORIII</acronym>
  <official_title>A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, &amp; Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seres Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seres Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days&#xD;
      in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group&#xD;
      II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to&#xD;
      reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks after&#xD;
      initiation of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled,&#xD;
      parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in&#xD;
      adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI&#xD;
      episodes within 12 months, inclusive of the current episode. This study is designed to&#xD;
      demonstrate the superiority of SER-109 versus placebo to reduce recurrence of Clostridium&#xD;
      difficile infection (CDI) in adults who have received antibacterial drug treatment for&#xD;
      recurrent CDI (RCDI), based on the proportion of subjects experiencing a CDI recurrence&#xD;
      requiring antibiotic treatment up to 8 weeks after initiation of treatment. Approximately 188&#xD;
      subjects with a history of CDI, diarrhea and a positive C. difficile toxin test result on a&#xD;
      stool sample, who have responded to standard-of-care (SOC) antibiotic treatment will be&#xD;
      enrolled. Subjects will be randomly assigned, in a 1:1 ratio, to 1 of 2 treatment groups&#xD;
      (Treatment Group I [SER-109] or Treatment Group II [Placebo]) and stratified by age (&lt;65&#xD;
      years; ≥65 years), as well as antibiotic regimen for the qualifying episode (vancomycin;&#xD;
      fidaxomicin).&#xD;
&#xD;
      Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days&#xD;
      in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group&#xD;
      II.&#xD;
&#xD;
      Subjects with confirmed CDI recurrence, as defined in the Protocol, up to 8 weeks after&#xD;
      administration of SER-109 or placebo treatment, may be eligible to enroll in the open-label&#xD;
      SER-109 extension study (Study SERES-013).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">July 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of CDI as determined by a toxin assay up to 8 weeks after initiation of treatment</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Recurrence of CDI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SER-109 as assessed by incidence of AEs, lab results, vital signs, and physical examination findings</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Safety and tolerability of SER-109</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of CDI from initiation of treatment as determined by a toxin assay</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Time to recurrence of CDI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of CDI, as determined by a toxin assay, up to 4, 12 and 24 weeks after initiation of treatment in each treatment group</measure>
    <time_frame>Up to 4, 12 and 24 weeks after treatment</time_frame>
    <description>Recurrence of CDI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>SER-109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received oral dose of SER-109</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SER-109</intervention_name>
    <description>SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors&#xD;
Other Names:&#xD;
Eubacterial Spores, Purified Suspension, Encapsulated</description>
    <arm_group_label>SER-109</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to initiation of any study-specific procedure or&#xD;
             treatment. The subject or their legally authorized representative must be able to&#xD;
             provide written informed consent and understand the potential risks and benefits from&#xD;
             study enrollment and treatment.&#xD;
&#xD;
          2. Male or female subject ≥ 18 years of age.&#xD;
&#xD;
          3. A qualifying episode of CDI as defined by:&#xD;
&#xD;
               1. ≥ 3 unformed stools per day for 2 consecutive days&#xD;
&#xD;
               2. A positive C. difficile stool toxin assay.&#xD;
&#xD;
               3. The requirement of CDI SOC antibiotic therapy (defined as 10 to 21 days of&#xD;
                  treatment with vancomycin [125 mg QID] and/or fidaxomicin [200 mg BID]).&#xD;
&#xD;
               4. An adequate clinical response following SOC antibiotic therapy, defined as (&lt;3&#xD;
                  unformed stools in 24 hours) for 2 or more consecutive days before randomization.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant, breastfeeding, lactating, or planning to become&#xD;
             pregnant during the study.&#xD;
&#xD;
          2. Known or suspected toxic megacolon and/or known small bowel ileus.&#xD;
&#xD;
          3. Admitted to or expected to be admitted to an intensive care unit for medical reasons&#xD;
             (not just boarding). Note: nursing homes, rehabilitation, assisted living centers and&#xD;
             acute care hospitals are acceptable.&#xD;
&#xD;
          4. Absolute neutrophil count of &lt;500 cells/ml^3&#xD;
&#xD;
          5. Major gastrointestinal surgery (e.g. significant bowel resection or diversion) within&#xD;
             3 months before enrollment (this does not include appendectomy or cholecystectomy), or&#xD;
             any history of total colectomy or bariatric surgery (bariatric surgery which does not&#xD;
             disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are&#xD;
             permitted).&#xD;
&#xD;
          6. History of active inflammatory bowel disease (ulcerative colitis, Crohn's disease,&#xD;
             microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel&#xD;
             disease in the past 3 months.&#xD;
&#xD;
          7. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for&#xD;
             active malignancy (subjects on maintenance chemotherapy may only be enrolled after&#xD;
             consultation with the study medical monitor).&#xD;
&#xD;
          8. Any history of fecal microbiota transplantation (FMT) within the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa von Moltke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seres Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <disposition_first_submitted>June 21, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>June 21, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 24, 2021</disposition_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

